Bonvalot S, Gronchi A, Le Péchoux C, et al. - Researchers investigated the effect of preoperative radiotherapy plus surgery vs surgery alone on abdominal recurrence-free survival of patients suffering from primary retroperitoneal sarcoma, in this open-label, randomised, phase 3 study (EORTC-62092). This study was done in 13 countries in Europe and North America. Eligible patients were randomized (1:1) to receive either surgery alone or preoperative radiotherapy followed by surgery. In the radiotherapy plus surgery group and in the surgery only group, the median abdominal recurrence-free survival was found to be 4·5 years and 5·0 years, respectively. In 30 (24%) of 127 patients in the radiotherapy plus surgery group and in 13 (10%) of 128 patients in the surgery alone group, serious adverse events were experienced. Based on these findings, experts recommended not considering preoperative radiotherapy as standard of care treatment for retroperitoneal sarcoma.